- What Each Pathway Covers
- The Risk-Tier Fork: A Key Difference in the Device Pathway
- Review Timelines and the 30-Day Default
- Downstream Marketing Pathways: Why the Starting Point Matters
- When Both an IDE and an IND Apply
- When an IDE Is Not Required
- How This Decision Affects Your FIH Strategy in Latin America
- Making the IDE vs IND Decision: A Practical Framework
- FAQs
- Conclusion
If you are building a medical device and preparing for first-in-human testing, one of the earliest regulatory decisions you face is whether your clinical program falls under an Investigational Device Exemption (IDE) or an Investigational New Drug (IND) application. The IDE vs IND question shapes everything downstream: which FDA center reviews your submission, how long that review takes, what risk classification applies, and which marketing pathway you are ultimately building toward.
Getting this wrong early is costly. Sponsors who structure their clinical evidence under the wrong framework can face submission rejections, protocol redesigns, or data packages that do not support their intended U.S. clearance or approval pathway. This article explains the core differences between IDE and IND, walks through the decision logic, and covers the scenarios where both apply simultaneously.
What Each Pathway Covers
IDE: The Medical Device Route
An IDE allows a medical device that has not yet received FDA clearance or approval to be used in a clinical study on human subjects. As ora.research.ucla.edu noted in its 2021 report, a medical device is considered investigational if it is not approved for marketing in the U.S. or is being clinically evaluated for a new indication. The IDE framework is governed by 21 CFR Part 812 and reviewed by the Center for Devices and Radiological Health (CDRH).
The IDE pathway exists to generate the clinical evidence a sponsor needs to support a downstream 510(k), De Novo, PMA, or Humanitarian Device Exemption (HDE) submission. The clinical data collected under an IDE is the foundation for those marketing applications.
IND: The Drug and Biologic Route
An IND application covers investigational drugs, biologics, and certain gene therapies. It is governed by 21 CFR Part 312 and reviewed by either the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER), depending on the product type. Radiopharmaceuticals, for example, typically fall under CDER or CBER depending on their intended use and mechanism.
The IND pathway leads downstream to a New Drug Application (NDA) or Biologics License Application (BLA). Clinical development is phase-based: Phase 1 for safety and dose-finding, Phase 2 for efficacy signals, Phase 3 for pivotal evidence.
The Risk-Tier Fork: A Key Difference in the Device Pathway
One of the most consequential distinctions between IDE and IND is the risk-tiering step that exists only in the device pathway. According to CASRAI, the medical device pathway requires a classification of significant-risk (SR) or non-significant-risk (NSR) — a step with no equivalent in the drug pathway.
This classification determines how much FDA oversight your study carries.
Significant-Risk (SR) devices require a full IDE application submitted to and approved by FDA before the study begins. SR devices are those that present a potential for serious risk to health, safety, or welfare — implantable devices, devices that support or sustain human life, and devices used in diagnosing or treating serious conditions all fall into this category.
Non-Significant-Risk (NSR) devices do not require a formal IDE submission to FDA. Instead, the sponsor obtains approval from an Institutional Review Board (IRB) or Ethics Committee (EC) and proceeds under an abbreviated IDE. Informed consent, proper labeling, and study monitoring are still required — but the FDA review step is replaced by IRB oversight.
This fork matters enormously for startup planning. An NSR determination can compress your pre-study timeline substantially. An SR determination puts you in a formal FDA review cycle before a single patient is enrolled.
Review Timelines and the 30-Day Default
For IND applications, CASRAI notes that FDA uses a 30-day default review period, after which a sponsor may proceed unless a clinical hold is issued. If FDA does not respond within 30 days, the sponsor is cleared to begin the study.
The IDE review process works differently. FDA has 30 days to review an IDE application, but for SR devices, FDA must affirmatively approve the IDE before the study begins. There is no default-to-proceed mechanism for a full IDE. That distinction is operationally significant: an IND sponsor can plan around a 30-day window with reasonable confidence, while an IDE sponsor for an SR device must wait for explicit approval.
Both pathways also require IRB or EC approval at the site level, running in parallel to the FDA review. In the U.S., that parallel process can add weeks to months depending on the institution.
Downstream Marketing Pathways: Why the Starting Point Matters
The pathway you enter at the investigational stage determines the marketing application you will file later. This is not a technicality — it defines the evidence standard your clinical data must meet from day one.
| Starting Pathway | Governing Regulation | Reviewing Center | Downstream Application |
|---|---|---|---|
| IDE | 21 CFR Part 812 | CDRH | 510(k), De Novo, PMA, HDE |
| IND | 21 CFR Part 312 | CDER or CBER | NDA, BLA |
If you are a device company pursuing a 510(k) or PMA, your clinical data must be structured under the IDE framework and ISO 14155 to be accepted in that submission. Data collected under an IND structure will not substitute for IDE-governed device evidence in a CDRH review. The reverse is equally true.
This is why regulatory strategy alignment at the Pre-Sub stage is not optional. The FDA's Pre-Submission (Q-Sub) program exists precisely to resolve pathway questions before a sponsor commits resources to a clinical program.
When Both an IDE and an IND Apply
Combination products — those that combine a device component with a drug or biologic component — can require both an IDE and an IND. Drug-eluting stents, implantable drug delivery systems, and devices incorporating a biologic agent are all examples where both frameworks may apply.
In these cases, FDA assigns a primary mode of action (PMOA) to determine the lead reviewing center. If the device function is primary, CDRH leads. If the drug or biologic function is primary, CDER or CBER leads. The non-lead center still reviews the submission, but the lead center sets the standards and timelines.
Radiopharmaceutical developers face a version of this complexity. Compounds like Lu-177, Ac-225, and Ga-68 involve both a device delivery mechanism and a drug or biologic component, which means the regulatory strategy must account for both centers from the outset.
When an IDE Is Not Required
Not every device study requires an IDE. FDA exempts certain categories of device studies from the IDE requirement entirely:
- Studies of devices that are already legally marketed, when the study is not intended to determine safety or effectiveness for a new indication
- Diagnostic device studies that meet specific criteria, including no significant risk to subjects and use of cleared devices within their labeled indications
- Consumer preference studies that do not involve any risk to subjects
- Studies involving devices exempt under 21 CFR 812.2(c)
Whether your study qualifies for an exemption is part of the Pre-Sub conversation with FDA. Sponsors who assume an exemption applies without confirming it are exposed to significant compliance risk.
How This Decision Affects Your FIH Strategy in Latin America
For MedTech startups running first-in-human studies outside the U.S., the IDE vs IND determination has direct implications for how clinical data is structured and whether it will be accepted in a U.S. submission.
Data collected under ISO 14155 and structured per FDA 21 CFR 812.28 is accepted for U.S. IDE and IND submissions when properly structured. That qualifier matters. A study run in Panama, Colombia, or Chile under a CRO that does not anchor its protocol architecture to the sponsor's U.S. regulatory pathway will generate data that may not survive CDRH or CDER review.
bioaccess® anchors every FIH program to the sponsor's intended U.S. pathway from day one. Whether that pathway is IDE toward a PMA, IND toward a BLA, or a combination product strategy, the FIH-12™ program structures the protocol, data collection, and evidence package to meet the applicable FDA standard. FDA Pre-Sub and pathway alignment is the first of 9 workstreams — not an afterthought.
This approach has produced FDA-submissible evidence packages for sponsors across a range of device categories. The enVVeno Medical case study illustrates how a LATAM first-in-human program was structured to support what became the first-ever FDA IDE for a non-surgical replacement venous valve. The Cook Group case study documents a multi-site FIH program in Colombia with 142-plus INVIMA regulatory submissions managed, all structured for U.S. submission readiness.
Ophthalmic device sponsors can see a similar approach in the ClarVista Medical case study, where LATAM first-in-human data supported a program that ended in a ClarVista acquisition by Alcon. For sponsors in retinal therapy, the i-Lumen Scientific case study covers a novel device program for age-related macular degeneration run through the same framework.
The speed advantage in Latin America — where ethics and regulatory approvals have been observed in 30 to 90 days in Panama, El Salvador, Chile, and the Dominican Republic — only produces value if the data generated meets the FDA standard your downstream application requires. Pathway clarity before the study starts is what makes that speed useful rather than just fast.
Making the IDE vs IND Decision: A Practical Framework
Before filing anything, work through these questions in order.
1. What is your product? If it is a drug, biologic, or gene therapy with no device component, you are in IND territory. If it is a device with no drug or biologic component, you are in IDE territory. If it combines both, you need a PMOA determination.
2. What is your downstream marketing application? Targeting 510(k), De Novo, PMA, or HDE means your clinical data must be structured under the IDE framework. Targeting NDA or BLA means it must be structured under IND.
3. What is the risk classification of your device? SR or NSR — this determines whether you need a full IDE submission to FDA or can proceed under an abbreviated IDE with IRB approval.
4. Does your study qualify for an IDE exemption? Confirm with FDA through a Pre-Sub if there is any ambiguity.
5. Where are you running the study? If outside the U.S., confirm that your CRO structures data collection under ISO 14155 and 21 CFR 812.28 to ensure FDA acceptability.
FAQs
What is the difference between an IDE and an IND?
An IDE (Investigational Device Exemption) governs clinical studies of unapproved medical devices under 21 CFR Part 812, reviewed by CDRH. An IND (Investigational New Drug) governs clinical studies of drugs and biologics under 21 CFR Part 312, reviewed by CDER or CBER. The pathway you enter determines the downstream marketing application you can file and the evidence standard your clinical data must meet.
Which FDA center reviews IDE applications?
CDRH reviews IDE applications. IND applications are reviewed by CDER (drugs) or CBER (biologics), depending on the product type.
What is the difference between a significant-risk and non-significant-risk device?
A significant-risk (SR) device presents a potential for serious risk and requires a full IDE submission with FDA approval before the study begins. A non-significant-risk (NSR) device does not require a formal FDA submission; the sponsor proceeds under an abbreviated IDE with IRB or Ethics Committee approval.
Can a clinical study require both an IDE and an IND?
Yes. Combination products that include both a device component and a drug or biologic component may require both an IDE and an IND. FDA assigns a primary mode of action to determine the lead reviewing center, but both centers review the submission.
How long does FDA take to review an IDE application?
FDA has 30 days to review an IDE application. For significant-risk devices, FDA must affirmatively approve the IDE before the study begins — there is no default-to-proceed mechanism, unlike IND applications, where a sponsor may proceed after 30 days if no clinical hold is issued.
Does data collected in Latin America satisfy FDA IDE or IND requirements?
Data collected under ISO 14155 and structured per FDA 21 CFR 812.28 is accepted for U.S. IDE and IND submissions when properly structured. The critical factor is that the CRO managing the study anchors its protocol architecture and data collection to the sponsor's specific U.S. regulatory pathway from the start of the program.
When is an IDE not required for a device study?
IDE requirements do not apply to studies of legally marketed devices used within their cleared indications, certain diagnostic device studies meeting specific criteria, consumer preference studies without subject risk, and categories specifically exempted under 21 CFR 812.2(c). Sponsors should confirm any exemption claim through an FDA Pre-Submission before proceeding.
Conclusion
The IDE vs IND decision is not administrative paperwork. It is the regulatory foundation your entire clinical program is built on. Get it right before the protocol is written, before the CRO is engaged, and before a single patient is screened. A misclassified pathway, a misstructured data package, or an unconfirmed exemption assumption are expensive and time-consuming to correct.
If you are at the pre-clinical to IDE/IND-ready stage and need to map your pathway before your next funding milestone, bioaccess® builds that strategy into the first workstream of every FIH-12™ program. Visit bioaccessla.com to get your FIH roadmap.
Leave a Reply